A carregar...

BCL-2 inhibition – stemming the tide of myeloid malignancies

Leukemia stem cells (LSC) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. (Lagadinou et al., 2013) and (Goff et al., 2013) find that LSC can be selectively targeted by small molecule antagonists of anti-apoptotic BCL-2 family proteins.

Na minha lista:
Detalhes bibliográficos
Main Authors: Hogdal, Leah J., Letai, Anthony
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3705714/
https://ncbi.nlm.nih.gov/pubmed/23472867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2013.02.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!